Aevitas Wealth Management’s abrdn Life Sciences Investors HQL Stock Holding History

Aevitas Wealth Management’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-35	Closed	–	–	191
2019 Q1	$0	Hold	35	–	–	﹤0.01%	378
2018 Q4	$1K	Hold	35	–	–	﹤0.01%	372
2018 Q3	$1K	Hold	35	–	–	﹤0.01%	435
2018 Q2	$1K	Hold	35	–	–	﹤0.01%	410
2018 Q1	$1K	Hold	35	–	–	﹤0.01%	430
2017 Q4	$1K	Buy	+35	New	+$701	﹤0.01%	422

Other funds holding HQL

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Cohen & Steers New York $57.6B AUM 8.03% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

Aevitas Wealth Management's HQL Position: Q2 2019 in Review

Aevitas Wealth Management sold out of abrdn Life Sciences Investors (HQL) in Q2 2019, closing a stake of 35 shares.

Aevitas Wealth Management first reported a position in HQL in Q4 2017 and held it in 6 quarters. The position peaked at $1K in Q4 2018. 55 funds tracked by Wall St. Rank hold HQL as of Q2 2019.

Aevitas Wealth Management reported no remaining abrdn Life Sciences Investors position as of Q2 2019 after selling out during the quarter.
Aevitas Wealth Management sold 35 abrdn Life Sciences Investors shares in Q2 2019.
Aevitas Wealth Management first reported a position in abrdn Life Sciences Investors in Q4 2017 and held it in 6 quarters.
Aevitas Wealth Management's abrdn Life Sciences Investors position peaked at $1K in Q4 2018.
55 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2019.

Based on Aevitas Wealth Management's 13F filing for Q2 2019, filed 26 Jul 2019.